Achieved Record Revenue for 2024 and Growth of 31%;Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CALIFORNIA / ACCESS Newswire / February 26, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the ...

Encephalitis can be a debilitating condition, but many people have never even heard of it. A new global report looks at how we can improve diagnosis and treatment.

UCLA scientists have identified a potential new strategy for treating glioblastoma, the deadliest form of brain cancer, by ...

"We look forward to reporting topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab targeting frontotemporal dementia with a granulin gene mutation by the fourth quarter. Additionally, ...